drugset
drugset / Trial / NCT00830674

A Study of KRN23 in X-linked Hypophosphatemia

NCT00830674 ↗

Phase 1 Completed 42 enrolled Kyowa Kirin, Inc. Kyowa Hakko Kirin Pharma, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of KRN23 after a single intravenous (IV) and subcutaneous (SC) administration in XLH patients.

Timeline

Start
2008-12
Primary completion
2011-12
Completion
2013-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Burosumab Monoclonal antibody 0.003 mg/kg Intravenous
Subject Burosumab Monoclonal antibody 0.01 mg/kg Intravenous
Subject Burosumab Monoclonal antibody 0.03 mg/kg Intravenous
Subject Burosumab Monoclonal antibody 0.1 mg/kg Intravenous
Subject Burosumab Monoclonal antibody 0.3 mg/kg Intravenous
Subject Burosumab Monoclonal antibody 0.6 mg/kg Intravenous
Subject Burosumab Monoclonal antibody 1 mg/kg Intravenous

Indications

X-linked hypophosphatemic rickets